Stay updated with breaking news from Research Code. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
2021年7月14日，荣昌生物研发的维迪西妥单抗用于治疗HER2过表达局部晚期或转移性尿路上皮癌患者的新药提交上市申请，正式获国家药监局受理。 作为研发治疗肿瘤等疾病的创新性生物药物的荣昌生物制药（烟台）股份有限公司（下称“荣昌生物”，09995.HK），公司已于2020年11月9日在港交所上市，在2021年6月21日又向上交所提交了招股说明书，计划在H股和A股市场挂牌上市。如此接连着眼于资本市场，荣昌生物到底在关注着什么？ 未知的商业化市场 目...
管线“豪华” 荣昌生物2018年~2020年主要业绩指标图片来源：界面新闻研究部 巨资投入下，荣昌生物研发管线成色如何？ 与许多生物制药企业不同，荣昌生物避开了一些“扎堆”的靶点和技术路径。如荣昌生物开发的泰它西普属于同类首创(first-in-class)的B淋巴细胞刺激因子(BLyS)/增殖诱导配体(APRIL)双靶点药物。泰它西普可用于治疗系统性红斑狼疮(SLE)等多种B细胞介导的自身免疫性疾病。国内用于治疗系统性红斑狼疮的生物仅有葛兰素...
我国首个原创性抗体偶联药物(ADC)新药——维迪西妥单抗获得上市批准。
Does ocean acidification alter fish behavior? Fraud allegations create a sea of doubt May. 6, 2021 , 2:00 PM When Philip Munday discussed his research on ocean acidification with more than 70 colleagues and students in a December 2020 Zoom meeting, he wasn’t just giving a confident overview of a decade’s worth of science. Munday, a marine ecologist at James Cook University (JCU), Townsville, was speaking to defend his scientific legacy. Munday has co-authored more than 250 papers and drawn scores of aspiring scientists to Townsville, a mecca of marine biology on Australia’s northeastern...
Academic tussle as ancient relics from black market brought into country Weâre sorry, this service is currently unavailable. Please try again later. Dismiss By Michaela Boland Save Normal text size Advertisement A pair of 2000-year-old bark manuscripts that promise to unlock some mysteries of the birth of Buddhism have turned up in Australia, sparking an ethical and legal debate about whether they should be here. University of Sydney academic Dr Mark Allon sourced the ancient relics on the black market and then in 2019 established a crowdfunding campaign, seeking to raise $30,000 to fund...